People taking new weight loss drugs such as Wegovy and Ozempic may be facing an unexpected side effect that has nothing to do with nausea or digestion. Fresh research suggests that using GLP-1 medications can trigger strong social stigma, even when the drugs lead to successful weight loss.
A study led by Rice University and published in the International Journal of Obesity found that people who lose weight with GLP-1 drugs are often judged more harshly than those who slim down through diet and exercise. In some cases, they were even viewed more negatively than people who did not lose weight at all.
How The Stigma Was Measured
Researchers recruited 1 313 adults in the US to take part in two randomized online experiments. Participants were given short descriptions of a fictional 38-year-old person, with versions that differed in how much weight the person had lost, how they lost it, and whether they maintained the weight loss.
Some profiles described weight loss achieved with GLP-1 drugs, while others credited diet and exercise or no weight loss. Participants then rated each character on traits such as laziness, discipline, health, honesty, generosity, and how much they would like to spend time with that person.
Across most measures, characters who used GLP-1 drugs were viewed more negatively than those who lost weight through lifestyle changes. They were rated as lazier, less healthy, and less disciplined, and participants were less willing to associate with them socially.
Worse Views Than No Weight Loss
When GLP-1 users were compared with fictional people who had not lost weight, the differences were striking. Both groups drew similar levels of negative judgments, but GLP-1 users received lower scores on positive qualities such as honesty and generosity.
Surprisingly, participants said they would rather spend time with someone who had not lost weight than with someone who had used GLP-1 drugs to lose it. Lead author Erin Standen said the team expected some stigma but was surprised by its intensity and consistency.
In a follow-up experiment, the researchers examined attitudes toward people who regained weight after losing it. Regaining weight after stopping GLP-1 drugs was judged about as harshly as regaining weight after diet and exercise, while those who maintained the weight loss were viewed more favorably.
Why Social Perceptions Matter
The study relied on fictional profiles, so it cannot capture the full complexity of real-life relationships. Still, the findings point to a clear pattern: people may face judgment both for their body size and for how they choose to manage it, especially when medications are involved.
GLP-1 drugs, which mimic a hormone that helps regulate blood sugar and appetite, have transformed obesity treatment in recent years. Clinical trials show they can help patients lose around 10–15 percent of their body weight, with some newer agents achieving even greater results.
However, weight commonly returns after people stop taking these drugs, reflecting the chronic and relapsing nature of obesity. Health experts stress that obesity is a complex disease shaped by genetics, biology, environment, and social factors, not simply personal willpower.
Beyond The “Easy Way Out” Narrative
The researchers say their findings highlight how persistent beliefs about weight loss can clash with modern medicine. Many people still view drugs as an “easy way out,” even though GLP-1 therapies often require long-term use, careful monitoring, and can produce side effects.
Stigma can have real health consequences, influencing whether people seek treatment or continue it. If patients fear being labeled lazy or dishonest for using medication, they may avoid discussing options with doctors or abandon therapies that could lower their risk of diabetes, heart disease, and some cancers.
Specialists in obesity medicine argue that reframing public discussion is essential as GLP-1 drugs become more common worldwide. They say messaging should emphasize that obesity is treatable, that multiple approaches can be valid, and that using evidence-based medication is a legitimate and medically sound choice.
As demand for GLP-1 drugs surges and supplies remain limited in some markets, debates over fairness, access, and insurance coverage are intensifying. The new research adds another layer to the discussion, underscoring that social attitudes may be just as important as clinical data in determining who benefits from these therapies.
